NeuroCube® is designed to evaluate gait to assess the impact of treatments on motor impairment disorders and pain. It provides a view of a rodent’s movements, highlighting the differences between a normal and an impaired mouse using machine learning.
- NeuroCube® employs computer vision to detect changes in gait geometry (e.g., stride length, base width) and dynamics (e.g., swing time, speed) in rodent models of neurological disorders and pain.
- AI algorithms like those used in SmartCube® define and rank the features that define a phenotype and calculate a discrimination probability between the disease model and its control to determine onset of disease phenotype for pharmacological intervention.
The figure above shows gait geometry and dynamic features in the aged SOD1 mouse model of ALS.
Partnering with PsychoGenics
At PsychoGenics, we employ our Cube platforms with novel diverse chemical libraries to discover improved treatments for severely disabling neuropsychiatric disorders. In our quest for novel and improved treatments, we form strategic partnerships with biopharmaceutical companies. Through these collaborations, we provide access to NeuroCube® and our other Cube platforms, or license our groundbreaking discoveries, to those who share our vision of a brighter tomorrow for those struggling with mental illness.